HAVCR2 and central nervous system cancer: They demonstrated that patients with gliomas that had high TIM-3 and CD68 expression using the median expression as a threshold displayed significantly lower survival compared to glioma patients who expressed either high TIM-3/low CD68, low TIM-3/high CD68, or low TIM-3/low CD68 [88].